Current Report Filing (8-k)
May 02 2014 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 28, 2014
SEQUENOM, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
DELAWARE |
|
000-29101 |
|
77-0365889 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
3595 JOHN HOPKINS COURT
SAN DIEGO, CALIFORNIA 92121
(Address of Principal Executive Offices)
(858) 202-9000
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On April 28, 2014, Allan T. Bombard, M.D., Chief Medical Officer of Sequenom, Inc. (the
Company), informed the Company that he will retire from employment with the Company as of the Companys next annual meeting of stockholders on June 10, 2014.
Dr. Bombard has served as our Chief Medical Officer since January 2009 and as one of our CLIA/CAP Laboratory Directors since June 2010.
2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
SEQUENOM, INC. |
|
|
|
Date: May 2, 2014 |
|
By: |
|
/s/ R. William Bowen |
|
|
|
|
R. William Bowen |
|
|
|
|
Senior Vice President and General Counsel |
3.
Sequenom, Inc. (NASDAQ:SQNM)
Historical Stock Chart
From May 2024 to Jun 2024
Sequenom, Inc. (NASDAQ:SQNM)
Historical Stock Chart
From Jun 2023 to Jun 2024